Argent BioPharma (ASX:RGT) is working with European pharmaceutical manufacturer ECCPharm, according to a Wednesday filing with the Australian bourse.
Under the agreement, ECCPharm will handle manufacturing and batch release responsibilities for Argent's cannabinoid therapies, CannEpil and CogniCann, ensuring access to these therapies through early patient programs in European countries, including Ireland, the UK, and Germany, the filing said.
As part of the deal, ECCPharm will oversee the transfer of manufacturing operations from Argent BioPharma's current facilities to ECCPharm's production facility in North Macedonia, the filing added.
Argent will cover all costs associated with the technology transfer and retain ownership of its research and development pipeline, along with all intellectual property rights.
Shares of the company rose past 17% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。